Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mark

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Science (New York, N.Y.)|August 23, 2003
Preparation of a pure molecular quantum gasJens Herbig, Tobias Kraemer, Michael Mark, et al.
European Journal of Pharmacology|August 28, 2014
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese ratHenrik H Hansen, Gitte Hansen, Sarah Paulsen, et al.
British Journal of Pharmacology|December 3, 2017
Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosisManuel Baader, Tom Bretschneider, Andre Broermann, et al.
Swiss Medical Weekly|January 21, 2025
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in SwitzerlandTämer El Saadany, Judith Lupatsch, Michael Mark, et al.
Diabetes|May 22, 2016
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL CatabolismFrançois Briand, Eric Mayoux, Emmanuel Brousseau, et al.
European Journal of Pharmacology|February 18, 2014
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF ratsRobert B Jones, Steven P Vickers, Sharon C Cheetham, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 12, 2012
The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob miceChristoph Schürmann, Andreas Linke, Kerstin Engelmann-Pilger, et al.
The Journal of Biological Chemistry|October 11, 2012
CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) is a tail-anchored protein in the endoplasmic reticulum (ER) of insulinoma cellsSilvia Brambillasca, Anke Altkrueger, Sara Francesca Colombo, et al.
BMC Cancer|March 28, 2013
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivorsArnoud J Templeton, Beat Thürlimann, Michael Baumann, et al.
Plos One|July 5, 2012
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityMatthias Kern, Nora Klöting, Heiko G Niessen, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Science (New York, N.Y.)|August 23, 2003
Preparation of a pure molecular quantum gasJens Herbig, Tobias Kraemer, Michael Mark, et al.
European Journal of Pharmacology|August 28, 2014
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese ratHenrik H Hansen, Gitte Hansen, Sarah Paulsen, et al.
British Journal of Pharmacology|December 3, 2017
Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosisManuel Baader, Tom Bretschneider, Andre Broermann, et al.
Swiss Medical Weekly|January 21, 2025
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in SwitzerlandTämer El Saadany, Judith Lupatsch, Michael Mark, et al.
Diabetes|May 22, 2016
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL CatabolismFrançois Briand, Eric Mayoux, Emmanuel Brousseau, et al.
European Journal of Pharmacology|February 18, 2014
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF ratsRobert B Jones, Steven P Vickers, Sharon C Cheetham, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 12, 2012
The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob miceChristoph Schürmann, Andreas Linke, Kerstin Engelmann-Pilger, et al.
The Journal of Biological Chemistry|October 11, 2012
CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) is a tail-anchored protein in the endoplasmic reticulum (ER) of insulinoma cellsSilvia Brambillasca, Anke Altkrueger, Sara Francesca Colombo, et al.
BMC Cancer|March 28, 2013
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivorsArnoud J Templeton, Beat Thürlimann, Michael Baumann, et al.
Plos One|July 5, 2012
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityMatthias Kern, Nora Klöting, Heiko G Niessen, et al.
Pageof 9